Trial Profile
A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Tomivosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 30 May 2018 Status changed from active, no longer recruiting to discontinued.
- 24 Apr 2018 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
- 24 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.